FDA 483 - Bora Pharmaceuticals Injectables Inc

Cangene BioPharma in Baltimore, MD, received a Form 483 following a Pre-Approval Inspection. The inspection revealed significant deficiencies in process validation, including failed batches and inadequate testing. Additionally, the firm lacked sufficient controls to prevent cross-contamination and demonstrated insufficient cleaning verification for product contact equipment.